Chinese medical stocks shifting to A-share listings on the promise of higher valuations

Chinese medical companies are turning away from the HKEx in favor of the A-share market, attracted by valuation premiums and a stronger appreciation for their brands.

The trend will gather more momentum in the year ahead as China is expected to loosen its IPO approval system 2Q, sources polled by this news service said.
In the last 12 months, Chinese healthcare companies such as Xiuzheng Pharmaceutical, Beijing Konrus Pharmaceutical, Zhuhai Blue Ocean Strategy that had mandated banks for Hong Kong listings have withdrawn their plans in order to pursue A-share market IPOs, according to fillings from Hong Kong Stock exchange.